

From: Marilyn Jones [REDACTED]  
Sent: 06 February 2009 21:55  
To: Jeremy Powell  
Subject: Fw: Head and neck cancer (squamous cell carcinoma) - cetuximab - ACD  
Attachments: Cetuximab for R&M SCCHN ACD.pdf; Cetuximab for R&M SCCHN Evaluation Report.pdf

1) I believe all the available and relevant evidence has been taken into account including the one randomised controlled trial provided by manufacturer. 3.2

2) I consider the summaries of clinical cost effectiveness are reasonable interpretations of the evidence, which should that in some instances the subgroups were too small casting doubt of the results of cost effectiveness 3.14

Cetuximab requires more frequent administration than chemotherapy and if the disease responds treatment has to continue until disease progression occurs incurring greater costs, and patients tend to survive longer. Other treatments and palliative care can involve additional NHS costs. 3.18

3) The provisional recommendations of the Appraisal Committee, are, I believe sound - they pointed out that life years gained with the addition of cetuximab to chemotherapy was the equivalent of 68 days. 4.7

4) Personally I do not feel there are any equality related issues not covered in the ACD.

Marilyn Jones  
Patient Expert  
National Association Of Laryngectomee Clubs

From: Paleri, Vinidh [REDACTED]  
Sent: 23 January 2009 09:26  
To: David Bevan  
Subject: RE: Head and neck cancer (squamous cell carcinoma) -  
cetuximab -  
ACD

Follow Up Flag: Follow up  
Flag Status: Completed

I agree with the contents of the ACD.

Vin  
Vinidh Paleri MS FRCS(ORL-HNS)

[REDACTED]